NEW YORK (GenomeWeb News) – Investment bank Piper Jaffray has initiated coverage of PerkinElmer with an Overweight rating and a $46 price target.

Analyst William Quirk cited PerkinElmer's newborn screening business and expansion into high-growth markets as primary factors for its rating of the stock. He noted that PerkinElmer holds an approximately 65 percent share of the $200 million worldwide market for newborn screening. Further, that market is expected to grow to $1 billion as the rest of the world catches up to US newborn screening levels.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.